Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2016 1
2017 2
2018 3
2019 2
2020 1
2021 2
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 2 Constipation, CTCAE"
Page 1
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.
Leary A, Oaknin A, Trigo JM, Moreno V, Delord JP, Boni V, Braña I, Fernández C, Kahatt C, Nieto A, Cullell-Young M, Zeaiter A, Subbiah V. Leary A, et al. Eur J Cancer. 2023 Oct;192:113259. doi: 10.1016/j.ejca.2023.113259. Epub 2023 Jul 28. Eur J Cancer. 2023. PMID: 37634282 Free article.
METHODS: Data were pooled from 554 patients: 335 from all nine tumour-specific cohorts of the phase II basket trial and 219 from a randomised phase III trial (CORAIL) in platinum-resistant ovarian cancer. Events and laboratory abnormalities were graded …
METHODS: Data were pooled from 554 patients: 335 from all nine tumour-specific cohorts of the phase II basket trial and 219 from a …
Phase II Trial of Flaxseed to Prevent Acute Complications After Chemoradiation for Lung Cancer.
Lim TL, Pietrofesa RA, Arguiri E, Koumenis C, Feigenberg S, Simone CB 2nd, Rengan R, Cengel K, Levin WP, Christofidou-Solomidou M, Berman AT. Lim TL, et al. J Altern Complement Med. 2021 Oct;27(10):824-831. doi: 10.1089/acm.2020.0542. Epub 2021 Jun 23. J Altern Complement Med. 2021. PMID: 34161146 Clinical Trial.
The primary outcomes were overall adverse events, with particular focus on Grade 3 RP, and flaxseed tolerability. Adverse events were graded according to CTCAE v4.0. ...There were no cases of Grade 2 RP. Six patients (32%) developed Grade …
The primary outcomes were overall adverse events, with particular focus on Grade 3 RP, and flaxseed tolerability. Adverse events were …
Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis.
Dutz A, Agolli L, Baumann M, Troost EGC, Krause M, Hölscher T, Löck S. Dutz A, et al. Acta Oncol. 2019 Jun;58(6):916-925. doi: 10.1080/0284186X.2019.1581373. Epub 2019 Mar 18. Acta Oncol. 2019. PMID: 30882264
Results: There were no significant differences in GI and GU toxicities between both treatment groups except for late urinary urgency, which was significantly lower after PBT (IMRT: 25.0%, PBT: 0%, p = .047). Late GU toxicities and obstruction grade 2 were significan …
Results: There were no significant differences in GI and GU toxicities between both treatment groups except for late urinary urgency, which …
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.
Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer B, Wadlow R, Shore ND, Olson WC, Stambler N, DiPippo VA, Israel RJ. Petrylak DP, et al. Prostate. 2020 Jan;80(1):99-108. doi: 10.1002/pros.23922. Epub 2019 Nov 19. Prostate. 2020. PMID: 31742767 Clinical Trial.
METHODS: A total of 119 (84 chemotherapy-experienced and 35 chemotherapy-naive) subjects were administered PSMA ADC 2.5 or 2.3 mg/kg IV q3w for up to eight cycles. Antitumor activity (best percentage declines in PSA and CTCs from baseline and tumor responses through …
METHODS: A total of 119 (84 chemotherapy-experienced and 35 chemotherapy-naive) subjects were administered PSMA ADC 2.5 or 2.3 …
Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study.
Schenk H, Holle D, Nsaka M, Kleinschnitz C, Glas M, Scheffler A. Schenk H, et al. J Headache Pain. 2022 May 11;23(1):55. doi: 10.1186/s10194-022-01426-8. J Headache Pain. 2022. PMID: 35538414 Free PMC article.
All reported AEs, regardless of their severity, were included. AEs were graded using the common terminology criteria for adverse events (CTCAE). ...RESULTS: The proportion of patients who reported at least one AE were stable over the course of 12 months (after 3mo = …
All reported AEs, regardless of their severity, were included. AEs were graded using the common terminology criteria for adverse even …
Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer.
Montemurro F, Mittica G, Cagnazzo C, Longo V, Berchialla P, Solinas G, Culotta P, Martinello R, Foresto M, Gallizioli S, Calori A, Grasso B, Volpone C, Bertola G, Parola G, Tealdi G, Giuliano PL, Aglietta M, Ballari AM. Montemurro F, et al. JAMA Oncol. 2016 Apr;2(4):445-52. doi: 10.1001/jamaoncol.2015.4720. JAMA Oncol. 2016. PMID: 26720497
IMPORTANCE: Patient perspective on chemotherapy-related adverse effects is being increasingly acknowledged both in experimental clinical trials and in clinical practice. OBJECTIVE: To evaluate a 10-item, paper questionnaire derived from the US National Cancer Instit …
IMPORTANCE: Patient perspective on chemotherapy-related adverse effects is being increasingly acknowledged both in experimental clinical …
A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma.
Chang C, Li X, Cheng K, Cai Z, Xiong J, Lv W, Li R, Zhang P, Cao D. Chang C, et al. Oncologist. 2023 Jul 5;28(7):e575-e584. doi: 10.1093/oncolo/oyac146. Oncologist. 2023. PMID: 35930304 Free PMC article. Clinical Trial.
For patients with a body surface area of more than 1.5 m2, 3 DLTs in 7 patients were detected at cohort of S-1 100 mg (grade 3 thrombocytopenia with hemorrhage, grade 3 rash, and grade 3 mucositis/stomatitis). ...The most frequent nonhematologic AEs of any …
For patients with a body surface area of more than 1.5 m2, 3 DLTs in 7 patients were detected at cohort of S-1 100 mg (grade 3 thromb …
Safety and antitumor activity of arsenic trioxide plus infusional 5-fluorouracil, leucovorin, and irinotecan as second-line chemotherapy for refractory metastatic colorectal cancer: A pilot study from South India.
Lakshmaiah KC, Chaudhuri T, Babu GK, Lokanatha D, Jacob LA, Suresh Babu MC, Rudresha AH, Lokesh KN, Rajeev LK. Lakshmaiah KC, et al. Indian J Cancer. 2017 Oct-Dec;54(4):631-633. doi: 10.4103/ijc.IJC_374_17. Indian J Cancer. 2017. PMID: 30082548 Free article.
MATERIALS AND METHODS: Patients were administered ATO 0.15 mg/kg/day on days 1-2 along with FOLFIRI regimen at standard doses every 2 weeks, until disease progression, unacceptable toxicity, or patients' refusal. ...Median progression-free survival was 5.3 months (9 …
MATERIALS AND METHODS: Patients were administered ATO 0.15 mg/kg/day on days 1-2 along with FOLFIRI regimen at standard doses every …
Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study.
Jensen NBK, Pötter R, Kirchheiner K, Fokdal L, Lindegaard JC, Kirisits C, Mazeron R, Mahantshetty U, Jürgenliemk-Schulz IM, Segedin B, Hoskin P, Tanderup K; EMBRACE Collaborative Group. Jensen NBK, et al. Radiother Oncol. 2018 Jun;127(3):431-439. doi: 10.1016/j.radonc.2018.05.016. Epub 2018 Jun 4. Radiother Oncol. 2018. PMID: 29880222
RESULTS: At 3/5 years the actuarial incidence of bowel morbidity grade 3-4 was 5.0%/5.9%, including incidence of stenosis/stricture/fistula of 2.0%/2.6%. Grade 1-2 morbidity was pronounced with prevalence rates of 28-33% during follow-up. ...
RESULTS: At 3/5 years the actuarial incidence of bowel morbidity grade 3-4 was 5.0%/5.9%, including incidence of stenosis/stricture/f …
A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.
Matei D, Ghamande S, Roman L, Alvarez Secord A, Nemunaitis J, Markham MJ, Nephew KP, Jueliger S, Oganesian A, Naim S, Su XY, Keer H, Azab M, Fleming GF. Matei D, et al. Clin Cancer Res. 2018 May 15;24(10):2285-2293. doi: 10.1158/1078-0432.CCR-17-3055. Epub 2018 Mar 2. Clin Cancer Res. 2018. PMID: 29500276 Free PMC article. Clinical Trial.
No DLTs were observed in the subsequent 14 patients. Grade 3 adverse events 10% were neutropenia, leukopenia, anemia, nausea, vomiting, ascites, constipation, hypokalemia, pulmonary embolism, small-intestinal obstruction, and thrombocytopenia. Three patients had a p …
No DLTs were observed in the subsequent 14 patients. Grade 3 adverse events 10% were neutropenia, leukopenia, anemia, nausea, vomitin …
14 results